In addition, CRL4 repression and its substrate CDT1 accumulation are key biochemical events contributing to the genotoxic effects of the anti-cancer agent MLN4924, which inhibits CRL4 activity by preventing neddylation in ovarian cancer cells, suggesting CRL4 is a potential drug target in ovarian cancers3. The gene discussed is IL17RB; the disease is ovarian carcinoma.